

# John O'donnell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/240423/publications.pdf>

Version: 2024-02-01

11  
papers

440  
citations

1163117  
8  
h-index

1281871  
11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

531  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | ETX2514 is a broad-spectrum $\hat{1}^2$ -lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including <i>Acinetobacter baumannii</i> . <i>Nature Microbiology</i> , 2017, 2, 17104.               | 13.3 | 187       |
| 2  | Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrhoeae</i> , Including Multi-Drug-Resistant Isolates. <i>ACS Infectious Diseases</i> , 2020, 6, 1332-1345.                      | 3.8  | 73        |
| 3  | Rational design of a new antibiotic class for drug-resistant infections. <i>Nature</i> , 2021, 597, 698-702.  | 27.8 | 69        |
| 4  | Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine $\hat{1}^2$ -Lactamases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12511-12525.                                   | 6.4  | 44        |
| 5  | Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .        | 3.2  | 17        |
| 6  | Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .                          | 3.2  | 15        |
| 7  | Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the $\hat{1}^2$ -Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. <i>ACS Infectious Diseases</i> , 2020, 6, 1378-1388. | 3.8  | 13        |
| 8  | Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a $\hat{1}^2$ -Lactamase Inhibitor, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .                 | 3.2  | 11        |
| 9  | A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1423-1430.    | 3.1  | 5         |
| 10 | Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0129221.                  | 3.2  | 5         |
| 11 | Human Pharmacokinetics and Dose Projection of ETX2514/Sulbactam Combination for Use in the Treatment of Infections Caused by <i>Acinetobacter baumannii</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .              | 0.9  | 1         |